Suboxone sales down as opioid addiction drug market intensifies
Orexo removes overhang on shares with key court win | Evaluate
Domstol afviser omhøring af patentsag mellem Teva og Novo-firmaet Orexo — MedWatch
Full Year Report incl. Q4 2017
Teva, denying 'any liability,' set aside $646M for opioid settlements. Here's why | Fierce Pharma
Opioid Use Disorder Market Growth to register a CAGR of 8.7% to reach USD US$ 4,911.8 Million by 2028 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, | Medgadget
Orexo misses out on millions after losing patent infringement suit against Actavis
Teva unloads plant, U.S. OTC line to PL Developments | Fierce Pharma
Orexo enters patent infringement litigation against Actavis
Teva Can Challenge Validity of Orexo Patent (Corrected)
Teva extends global rebrand with tailored marketing messages for caregivers | Fierce Pharma
District Court of Delaware rules that Actavis does not infringes with their Suboxone® and Subutex® generics
Type headline here
Teva Can Challenge Validity of Orexo Patent (Corrected)
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Fast-dissolving opioid dependence tablet wins EU recommendation - Drug Delivery Business
Orexo soars after winning opioid drug appeal against Teva | Reuters
In opioid case, NY wants to probe Teva's control of Teva USA
In opioid case, NY wants to probe Teva's control of Teva USA
Opioid Use Disorder Market Is Booming Worldwide 2023-2030 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. - Digital Journal
Teva kept quiet for weeks on forthcoming generics blow: report | Fierce Pharma
